If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
<br /> TREATMENT STRATEGIES<br /> ONCOLOGY<br /> Volume 2 Issue 1<br /> <br /> • Breast Cancer<br /> • Genitourinary Tumors<br /> • Leukemia, Myelodysplasia and Transplantation<br /> • Lung Cancer<br /> • Lymphoma<br /> • Neuro-oncology<br /> • Sarcoma<br /> <br /> Articles include:<br /> Conventional and Novel Therapeutic Strategies in Acute<br /> Promyelocytic Leukemia Cancer<br /> <br /> Dynamic Risk Stratification of Prostate Cancer with Prostate-specific<br /> Antigen Kinetics: Towards Personalized Care in Recurrent Disease<br /> <br /> Progress in Predictive and Prognostic Biomarkers in<br /> Gastrointestinal Cancers<br /> <br /> Salvage Chemotherapy with Bevacizumab for Recurrent<br /> Anaplastic Glioma<br /> <br /> Targeting Sarcoma in 2011: Emerging Paradigms and
TREATMENT STRATEGIESONCOLOGYVolume 2 Issue 1•
TREATMENT STRATEGIESONCOLOGYVolume 2 Issue 1•
SARCOMA: THE ONLY THING PROGRESSING IS THE DISEAS
SARCOMA: THE ONLY THING PROGRESSING IS THE DISEAS
TREATMENT STRATEGIESOncologyTreatment Strate
TREATMENT STRATEGIESOncologyTreatment Strate
NOWAPPROVEDVisit www.zytiga.com
NOWAPPROVEDVisit www.zytiga.com
CONTENTS...39101118
CONTENTS...39101118
394346495460
394346495460
737781849093
737781849093
22-25 FEBRUARY 2012 ISTANBUL, TURKEY
22-25 FEBRUARY 2012 ISTANBUL, TURKEY
EDITORIALADVISORYPANELincluding...Eduardo Ca
EDITORIALADVISORYPANELincluding...Eduardo Ca
Treatment Strategies - ForewordForewordby P
Treatment Strategies - ForewordForewordby P
ASCOAnnual2011Meeting Review03 - 07 June
ASCOAnnual2011Meeting Review03 - 07 June
R1Treatment Strategies - Congress Reviewwww
R1Treatment Strategies - Congress Reviewwww
Treatment Strategies - Congress Reviewdisease-sp
Treatment Strategies - Congress Reviewdisease-sp
Treatment Strategies - Congress ReviewPatients
Treatment Strategies - Congress ReviewPatients
Treatment Strategies - Congress ReviewNEW DA
Treatment Strategies - Congress ReviewNEW DA
Treatment Strategies - Congress ReviewData P
Treatment Strategies - Congress ReviewData P
TREATMENT STRATEGIESSERIES Visit the p
TREATMENT STRATEGIESSERIES Visit the p
Treatment Strategies - Congress Review Novarti
Treatment Strategies - Congress Review Novarti
Treatment Strategies - Congress ReviewAward High
Treatment Strategies - Congress ReviewAward High
Treatment Strategies - Congress Reviewcontinued
Treatment Strategies - Congress Reviewcontinued
Treatment Strategies - Congress ReviewASTELLAS P
Treatment Strategies - Congress ReviewASTELLAS P
Treatment Strategies - Congress ReviewBest of AS
Treatment Strategies - Congress ReviewBest of AS
Treatment Strategies - Congress ReviewNexavar® D
Treatment Strategies - Congress ReviewNexavar® D
CAMBRIDGERESEARCHCENTRE HEALTHC
CAMBRIDGERESEARCHCENTRE HEALTHC
Treatment Strategies - Congress ReviewNew Analys
Treatment Strategies - Congress ReviewNew Analys
Treatment Strategies - Congress Review RES
Treatment Strategies - Congress Review RES
Treatment Strategies - Congress ReviewTreatment
Treatment Strategies - Congress ReviewTreatment
Treatment Strategies - Congress Reviewscientific
Treatment Strategies - Congress Reviewscientific
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review
Treatment Strategies - Congress ReviewLactofe
Treatment Strategies - Congress ReviewLactofe
the Hsp90 complexes in tumor cells have a more ac
the Hsp90 complexes in tumor cells have a more ac
Treatment Strategies - Congress ReviewIn anot
Treatment Strategies - Congress ReviewIn anot
Treatment Strategies - Congress Review P
Treatment Strategies - Congress Review P
Treatment Strategies - Congress ReviewAAWD pl
Treatment Strategies - Congress ReviewAAWD pl
Treatment Strategies - Congress Reviewof the
Treatment Strategies - Congress Reviewof the
Treatment Strategies - Congress Review C
Treatment Strategies - Congress Review C
motivated or due to access issues.In the secon
motivated or due to access issues.In the secon
Treatment Strategies - Congress Reviewdramati
Treatment Strategies - Congress Reviewdramati
TREATMENT STRATEGIESSERIES Visit the p
TREATMENT STRATEGIESSERIES Visit the p
Treatment Strategies - Congress Review K
Treatment Strategies - Congress Review K
was administered orally once daily for three week
was administered orally once daily for three week
Treatment Strategies - Congress Reviewand eff
Treatment Strategies - Congress Reviewand eff
in several package inserts of the above-mentioned
in several package inserts of the above-mentioned
Treatment Strategies - Congress ReviewAZD2171
Treatment Strategies - Congress ReviewAZD2171
Treatment Strategies - Congress Review P
Treatment Strategies - Congress Review P
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review
be examined on an individual patient level for th
be examined on an individual patient level for th
Treatment Strategies - Congress ReviewNew
Treatment Strategies - Congress ReviewNew
ResultsOf the seven patients on study, the media
ResultsOf the seven patients on study, the media
CAMBRIDGERESEARCHCENTRE HEALTHC
CAMBRIDGERESEARCHCENTRE HEALTHC
Treatment Strategies - BiomarkersIntegrati
Treatment Strategies - BiomarkersIntegrati
Treatment Strategies - Biomarkersamong discov
Treatment Strategies - Biomarkersamong discov
trials and many more PoC hypotheses of equal meri
trials and many more PoC hypotheses of equal meri
Treatment Strategies - Biomarkersdata to be a
Treatment Strategies - Biomarkersdata to be a
concerning the predictive biomarker based clinica
concerning the predictive biomarker based clinica
Treatment Strategies - BiomarkersAdaptive Pred
Treatment Strategies - BiomarkersAdaptive Pred
Treatment Strategies - Biomarkersa de ned com
Treatment Strategies - Biomarkersa de ned com
Treatment Strategies - BiomarkersProgress
Treatment Strategies - BiomarkersProgress
Reactivity Characteristics Score/Classi catio
Reactivity Characteristics Score/Classi catio
Treatment Strategies - BiomarkersStudy N
Treatment Strategies - BiomarkersStudy N
dMMR tumors may derive less bene t given their ov
dMMR tumors may derive less bene t given their ov
Treatment Strategies - BiomarkersReferences1
Treatment Strategies - BiomarkersReferences1
treatment for metastatic colorectal cancer (mCRC)
treatment for metastatic colorectal cancer (mCRC)
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
dependent on glutamine for survival.55 Ready acce
dependent on glutamine for survival.55 Ready acce
Treatment Strategies - Brain and Spinal Co
Treatment Strategies - Brain and Spinal Co
ant-diabetic drug metformin has been suggested as
ant-diabetic drug metformin has been suggested as
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
those patients who are fragile or in poor health.
those patients who are fragile or in poor health.
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
survival in GBM patients, we do not believe that
survival in GBM patients, we do not believe that
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Brain and Spinal Cord Canc
Treatment Strategies - Breast CancerA Failur
Treatment Strategies - Breast CancerA Failur
estimation of belt e ectiveness by crash type, oc
estimation of belt e ectiveness by crash type, oc
Treatment Strategies - Breast Cancermid-point
Treatment Strategies - Breast Cancermid-point
Treatment Strategies - Developmental Therapeutics
Treatment Strategies - Developmental Therapeutics
Treatment Strategies - Developmental Therapeutics
Treatment Strategies - Developmental Therapeutics
others) and means to prevent rapid regeneration a
others) and means to prevent rapid regeneration a
Treatment Strategies - Developmental Therapeutics
Treatment Strategies - Developmental Therapeutics
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Gastrointestinal Tumors
Treatment Strategies - Genitourinary Tumors
Treatment Strategies - Genitourinary Tumors
limited value in the setting of early disease and
limited value in the setting of early disease and
Treatment Strategies - Genitourinary TumorsRef
Treatment Strategies - Genitourinary TumorsRef
Treatment Strategies - Genitourinary Tumors
Treatment Strategies - Genitourinary Tumors
Treatment Strategies - Genitourinary TumorsBev
Treatment Strategies - Genitourinary TumorsBev
anti-VEGF monoclonal antibodies are likely restri
anti-VEGF monoclonal antibodies are likely restri
Treatment Strategies - Genitourinary Tumorsle
Treatment Strategies - Genitourinary Tumorsle
Treatment Strategies - Genitourinary Tumorsca
Treatment Strategies - Genitourinary Tumorsca
Treatment Strategies - Gynecological Cancer
Treatment Strategies - Gynecological Cancer
plus topotecan arm enjoyed improved median overal
plus topotecan arm enjoyed improved median overal
Treatment Strategies - Gynecological Cancerin
Treatment Strategies - Gynecological Cancerin
and neck37,38 as well as the majority of cervical
and neck37,38 as well as the majority of cervical
Treatment Strategies - Gynecological Cancerel
Treatment Strategies - Gynecological Cancerel
Treatment Strategies - Gynecological CancerRef
Treatment Strategies - Gynecological CancerRef
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Leukemia, Myelodysplasia a
Treatment Strategies - Lung CancerLung Can
Treatment Strategies - Lung CancerLung Can
two groups being more pronounced at the 90 day ma
two groups being more pronounced at the 90 day ma
Treatment Strategies - Lung Cancertreatment r
Treatment Strategies - Lung Cancertreatment r
combination chemotherapy with carboplatin-paclita
combination chemotherapy with carboplatin-paclita
Treatment Strategies - Lung CancerReferences1
Treatment Strategies - Lung CancerReferences1
Treatment Strategies - Lung CancerSurvival
Treatment Strategies - Lung CancerSurvival
Treatment Strategies - Lung CancerGy, convent
Treatment Strategies - Lung CancerGy, convent
paclitaxel (45 mg/m) was initiated. The RT dose w
paclitaxel (45 mg/m) was initiated. The RT dose w
Treatment Strategies - Lung Cancerhigher dose
Treatment Strategies - Lung Cancerhigher dose
Treatment Strategies - MelanomaSee the Lig
Treatment Strategies - MelanomaSee the Lig
Treatment Strategies - Melanomaforti ed foods
Treatment Strategies - Melanomaforti ed foods
Treatment Strategies - MelanomaSunbeds Overkil
Treatment Strategies - MelanomaSunbeds Overkil
Treatment Strategies - MelanomaBiophys Mol Bi
Treatment Strategies - MelanomaBiophys Mol Bi
Treatment Strategies - Neuro-oncologySalva
Treatment Strategies - Neuro-oncologySalva
Treatment Strategies - Neuro-oncologyAuthor (R
Treatment Strategies - Neuro-oncologyAuthor (R
Treatment Strategies - Neuro-oncologyoften ap
Treatment Strategies - Neuro-oncologyoften ap
Treatment Strategies - Neuro-oncologyoligoden
Treatment Strategies - Neuro-oncologyoligoden
Treatment Strategies - New DiagnosticsRole o
Treatment Strategies - New DiagnosticsRole o
Treatment Strategies - New Diagnostics
Treatment Strategies - New Diagnostics
Treatment Strategies - New Diagnostics
Treatment Strategies - New Diagnostics
Treatment Strategies - Pediatric OncologyE
Treatment Strategies - Pediatric OncologyE
trial examined the e ect of MPH (0.6 mg/kg; 20mg
trial examined the e ect of MPH (0.6 mg/kg; 20mg
Treatment Strategies - Pediatric Oncologyindu
Treatment Strategies - Pediatric Oncologyindu
Treatment Strategies - Pediatric Oncologydiag
Treatment Strategies - Pediatric Oncologydiag
Treatment Strategies - Pediatric Oncologyof t
Treatment Strategies - Pediatric Oncologyof t
Paris, FranceNovember 3–5, 20113rd Ann
Paris, FranceNovember 3–5, 20113rd Ann
Treatment Strategies - SarcomaTargeting Sa
Treatment Strategies - SarcomaTargeting Sa
In this study by Joensuu et al. 400 patients were
In this study by Joensuu et al. 400 patients were
Treatment Strategies - Sarcomastable at 6 mon
Treatment Strategies - Sarcomastable at 6 mon
Treatment Strategies - Supportive CareA Br
Treatment Strategies - Supportive CareA Br
Treatment Strategies - Supportive CareProcedur
Treatment Strategies - Supportive CareProcedur
Treatment Strategies - Supportive CareScale It
Treatment Strategies - Supportive CareScale It
APOS 9TH ANNUAL CONFERENCE23-25 FEBRUARY 2012 -
APOS 9TH ANNUAL CONFERENCE23-25 FEBRUARY 2012 -
Treatment Strategies - Events ListingsUpc
Treatment Strategies - Events ListingsUpc
Treatment Strategies - Events ListingsPsychos
Treatment Strategies - Events ListingsPsychos
CARFILP-3417_M01_Prelaunch_Ad_TSO_UK.indd
CARFILP-3417_M01_Prelaunch_Ad_TSO_UK.indd
The Cambridge Research CentreCoppergate House16
The Cambridge Research CentreCoppergate House16